Concepts in in vivo siRNA delivery for cancer therapy

Authors

  • Christopher S. Gondi,

    1. Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, Illinois
    Search for more papers by this author
  • Jasti S. Rao

    Corresponding author
    1. Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, Illinois
    2. Department of Neurosurgery, University of Illinois College of Medicine at Peoria, Peoria, Illinois
    • Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, One Illini Drive, Peoria, IL 61605.
    Search for more papers by this author

Abstract

In vivo gene silencing using RNAi plays an important role in target validation and is advancing towards the development of RNAi-based therapeutics. RNAs were thought to have just two broad functions in cells as messenger RNAs (mRNAs) and ribosomal RNAs, but recently the relevance of microRNAs is becoming more clearly understood. mRNA molecules transmit information between DNA and protein and, as such, are vital intermediaries for gene expression. Ribosomal and transfer RNAs have structural, catalytic, and information-decoding roles in the process of protein synthesis, whereas microRNAs are regulators of gene expression. This review presents the early and intriguing successes of using siRNAs for in vivo gene silencing and its use as a possible cancer therapeutics. J. Cell. Physiol. 220: 285–291, 2009. © 2009 Wiley-Liss, Inc.

Ancillary